Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$236.75
-1.1%
$227.10
$171.18
$247.19
$26.13B0.55954,461 shs775,617 shs
Guardant Health, Inc. stock logo
GH
Guardant Health
$161.41
+0.2%
$159.65
$53.40
$176.58
$21.66B1.572.28 million shs2.40 million shs
Hinge Health Inc. stock logo
HNGE
Hinge Health
$92.20
+1.6%
$85.17
$30.08
$95.57
$7.44B1.381.56 million shs1.18 million shs
Labcorp Holdings Inc. stock logo
LH
Labcorp
$326.83
-1.4%
$305.79
$244.52
$341.80
$26.51B0.88676,493 shs438,649 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
-0.46%-2.00%+2.34%+19.36%+33.62%
Guardant Health, Inc. stock logo
GH
Guardant Health
-1.24%-4.44%+0.78%+28.21%+147.53%
Hinge Health Inc. stock logo
HNGE
Hinge Health
-0.91%-1.75%+13.94%+43.41%+58.84%
Labcorp Holdings Inc. stock logo
LH
Labcorp
-0.28%-1.49%+5.98%+24.68%+21.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$236.75
-1.1%
$227.10
$171.18
$247.19
$26.13B0.55954,461 shs775,617 shs
Guardant Health, Inc. stock logo
GH
Guardant Health
$161.41
+0.2%
$159.65
$53.40
$176.58
$21.66B1.572.28 million shs2.40 million shs
Hinge Health Inc. stock logo
HNGE
Hinge Health
$92.20
+1.6%
$85.17
$30.08
$95.57
$7.44B1.381.56 million shs1.18 million shs
Labcorp Holdings Inc. stock logo
LH
Labcorp
$326.83
-1.4%
$305.79
$244.52
$341.80
$26.51B0.88676,493 shs438,649 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
-0.46%-2.00%+2.34%+19.36%+33.62%
Guardant Health, Inc. stock logo
GH
Guardant Health
-1.24%-4.44%+0.78%+28.21%+147.53%
Hinge Health Inc. stock logo
HNGE
Hinge Health
-0.91%-1.75%+13.94%+43.41%+58.84%
Labcorp Holdings Inc. stock logo
LH
Labcorp
-0.28%-1.49%+5.98%+24.68%+21.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
2.54
Moderate Buy$235.31-1.21% Downside
Guardant Health, Inc. stock logo
GH
Guardant Health
2.96
Moderate Buy$183.7818.07% Upside
Hinge Health Inc. stock logo
HNGE
Hinge Health
2.83
Moderate Buy$100.578.36% Upside
Labcorp Holdings Inc. stock logo
LH
Labcorp
2.75
Moderate Buy$330.000.53% Upside

Current Analyst Ratings Breakdown

Latest HNGE, LH, DGX, and GH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2026
Guardant Health, Inc. stock logo
GH
Guardant Health
Reiterated RatingBuy$195.00
8/25/2026
Guardant Health, Inc. stock logo
GH
Guardant Health
Reiterated RatingBuy
8/12/2026
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
UpgradeBuy (B+)Buy (A-)
8/11/2026
Hinge Health Inc. stock logo
HNGE
Hinge Health
DowngradeStrong-BuyHold
8/10/2026
Hinge Health Inc. stock logo
HNGE
Hinge Health
Boost Price TargetBuy$85.00 ➝ $112.00
8/10/2026
Labcorp Holdings Inc. stock logo
LH
Labcorp
Set Price Target$355.00
8/5/2026
Hinge Health Inc. stock logo
HNGE
Hinge Health
Reiterated RatingOutperform$105.00
8/5/2026
Hinge Health Inc. stock logo
HNGE
Hinge Health
Boost Price TargetOutperform$75.00 ➝ $110.00
8/5/2026
Hinge Health Inc. stock logo
HNGE
Hinge Health
Set Price Target$105.00
8/5/2026
Hinge Health Inc. stock logo
HNGE
Hinge Health
Set Price Target$96.00
8/5/2026
Hinge Health Inc. stock logo
HNGE
Hinge Health
Boost Price TargetOverweight$97.00 ➝ $100.00
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$11.04B2.38$15.01 per share15.87$70.84 per share3.36
Guardant Health, Inc. stock logo
GH
Guardant Health
$982.02M21.27N/AN/A($1.66) per share-93.77
Hinge Health Inc. stock logo
HNGE
Hinge Health
$587.86M12.74N/AN/A$4.27 per share21.74
Labcorp Holdings Inc. stock logo
LH
Labcorp
$13.95B1.91$24.57 per share13.36$106.13 per share3.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$992M$9.4225.2819.902.209.18%16.01%7.27%10/20/2026 (Estimated)
Guardant Health, Inc. stock logo
GH
Guardant Health
-$416.28M-$3.49N/AN/AN/A-38.33%N/A-25.40%10/28/2026 (Estimated)
Hinge Health Inc. stock logo
HNGE
Hinge Health
-$528.26M$1.2872.5168.25N/A15.15%51.60%14.16%N/A
Labcorp Holdings Inc. stock logo
LH
Labcorp
$876.50M$12.0927.1416.661.886.99%16.74%7.81%10/27/2026 (Estimated)

Latest HNGE, LH, DGX, and GH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Hinge Health Inc. stock logo
HNGE
Hinge Health
$0.28$0.59+$0.31$0.52N/A$212.82 million
7/30/2026Q2 2026
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.7618-$0.42+$0.3418-$0.90$314.23 million$334.98 million
7/30/2026Q2 2026
Labcorp Holdings Inc. stock logo
LH
Labcorp
$4.78$4.99+$0.21$3.64$3.71 billion$3.73 billion
7/23/2026Q2 2026
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$2.82$3.12+$0.30$2.84$2.97 billion$3.04 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$3.441.44%+7.34%36.52%14 Years
Guardant Health, Inc. stock logo
GH
Guardant Health
N/AN/AN/AN/AN/A
Hinge Health Inc. stock logo
HNGE
Hinge Health
N/AN/AN/AN/AN/A
Labcorp Holdings Inc. stock logo
LH
Labcorp
$2.880.87%N/A23.82%N/A

Latest HNGE, DGX, LH, and GH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/12/2026
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
quarterly$0.861.45%10/6/202610/6/202610/21/2026
7/9/2026
Labcorp Holdings Inc. stock logo
LH
Labcorp
quarterly$0.720.86%8/28/20268/28/20269/11/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.72
1.59
1.46
Guardant Health, Inc. stock logo
GH
Guardant Health
N/A
4.03
3.71
Hinge Health Inc. stock logo
HNGE
Hinge Health
N/A
1.34
1.30
Labcorp Holdings Inc. stock logo
LH
Labcorp
0.69
1.80
1.53

Institutional Ownership

CompanyInstitutional Ownership
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
88.06%
Guardant Health, Inc. stock logo
GH
Guardant Health
92.60%
Hinge Health Inc. stock logo
HNGE
Hinge Health
N/A
Labcorp Holdings Inc. stock logo
LH
Labcorp
95.94%

Insider Ownership

CompanyInsider Ownership
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.88%
Guardant Health, Inc. stock logo
GH
Guardant Health
5.60%
Hinge Health Inc. stock logo
HNGE
Hinge Health
18.92%
Labcorp Holdings Inc. stock logo
LH
Labcorp
0.84%
CompanyEmployeesShares OutstandingFree FloatOptionable
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
57,000110.37 million109.40 millionOptionable
Guardant Health, Inc. stock logo
GH
Guardant Health
2,506134.20 million126.68 millionNot Optionable
Hinge Health Inc. stock logo
HNGE
Hinge Health
1,43780.69 million65.43 millionN/A
Labcorp Holdings Inc. stock logo
LH
Labcorp
71,00081.10 million80.42 millionOptionable

Recent News About These Companies

Labcorp (NYSE:LH) Sets New 12-Month High - Here's Why
Labcorp's Alzheimer's Disease Blood Test Cleared by FDA
Labcorp (NYSE:LH) Director Sells $954,060.00 in Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Quest Diagnostics stock logo

Quest Diagnostics NYSE:DGX

$236.75 -2.65 (-1.11%)
As of 03:58 PM Eastern

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Guardant Health stock logo

Guardant Health NASDAQ:GH

$161.41 +0.37 (+0.23%)
As of 04:00 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Hinge Health stock logo

Hinge Health NYSE:HNGE

$92.20 +1.44 (+1.59%)
As of 03:58 PM Eastern

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients. We have designed our platform to address a broad spectrum of MSK care—from acute injury, to chronic pain, to post-surgical rehabilitation. Members receive personalized and largely automated MSK care through our AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device, all designed and monitored by our AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Our platform can improve pain and function and reduce the need for surgeries, all while driving health equity by allowing members to engage in their exercise therapy sessions from anywhere and embrace movement as a way of life. There is no shortage of new technologies in the healthcare industry, yet the cost of care continues to rise. In other industries, the launch of new technologies has generally improved end-user experiences and lowered costs. In healthcare, however, new technologies have not always been successful in lowering the cost of care or improving clinical outcomes. We believe there are two key reasons for healthcare’s idiosyncratic response to technology: • Automating most aspects of care is difficult because so many healthcare interventions involve unstructured physical tasks. • The current framework for healthcare reimbursement has specific pathways to pay for care, which means new technologies are constrained to deliver within this framework. At Hinge Health, we have taken these challenges head-on. To address the automation of care, we have weaved together AI-enabled capabilities - such as our AI-powered motion tracking technology, TrueMotion, our proprietary FDA-cleared wearable device, Enso, and our AI-supported care team - to deliver scalable and personalized MSK care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. We have done this while improving our high member satisfaction over time. To address healthcare reimbursement constraints, we developed novel billing methods for our innovative technology by both directly selling to employers while also partnering with health plans, pharmacy benefit managers (“PBMs”), third-party administrators (“TPAs”), and other ecosystem entities to efficiently provide our platform to clients and members. While the MSK market is massive, existing solutions have fallen short as they are often expensive, ineffective, inconvenient to access, and delivered in a one-to-one or few-to-one care setting. Effective MSK care should be engaging, easy to use, and accessible anytime, anywhere. We developed Hinge Health to be simple and accessible, complete, personalized, and scalable. • Simple and accessible: We provide members access to our platform at no direct cost to them and without a copay or deductible. Members can access our broad spectrum of MSK care through a single on-demand app, designed to provide an engaging, seamless, and convenient digital experience whenever and wherever the member chooses. Potential members can complete a simple intake form, download the app, and start exercises soon thereafter. During the year ended December 31, 2024, approximately 64% of members were onboarded on the same day they completed their intake form, and approximately 75% of members were onboarded within the first week. • Complete: Our platform offers a wide range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. We also offer non-addictive and non-invasive pain relief via electrostimulation through our proprietary FDA-cleared wearable device, Enso, that is seamlessly integrated into our platform. • Personalized: Our platform delivers smarter care through AI and machine learning. Our AI model is trained on a large, proprietary MSK data set, and our technology is continuously learning and improving as each new member enrolls and engages with our programs, which creates a positive feedback loop. As of March 31, 2025, we had treated over one million members and our programs had tracked over 74 million activity sessions and 32 million member-reported outcome logs. We focus on personalization to keep members moving: from customized care plans to real-time in-app exercise feedback based on the member’s input and our proprietary motion tracking technology. • Scalable: Our AI-powered motion tracking technology, TrueMotion, allows us to deliver scalable and largely automated care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. While most of our programs provide members with access to a dedicated care team, our technology automates most aspects of care delivery while allowing our members to progress through their exercise therapy sessions on their own time. We have developed an efficient go-to-market model by working directly with our partners and clients. We seek to be the best solution on the market, the most validated solution on the market, and the easiest to buy. Our clients are primarily self-insured employers and include many of the nation’s leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many public sector self-insured employers, such as state and local city governments and labor unions. In most instances, we partner with clients’ health plans, TPAs, PBMs, or other ecosystem entities to reduce the friction of contracting, procurement, security and IT reviews, onboarding, and billing. We are also in the early stages of expanding to serve health plans’ fully-insured and Medicare Advantage populations and federal insurance plans. As of December 31, 2024, we had approximately 20 million contracted lives across more than 2,250 clients. We had active client agreements with 49% of the Fortune 100 companies and 42% of the Fortune 500 companies, as of December 31, 2024. Despite this progress, our current contracted lives only represent 5% of our total addressable market. We believe that we grow efficiently because of our scalable, repeatable go-to-market model. We sell through our direct sales force and our partners. Once we contract with a client, we are most often the sole digital MSK care provider offered to their contracted lives. Our average contract term is three years. For the term of each contract, we are able to enroll, engage, and re-engage the client’s eligible lives, driving a recurring, repeatable revenue model, which is demonstrated in our net dollar retention of 117% as of December 31, 2024. Our 12-month client retention rate was 98% as of December 31, 2024. Additionally, we have a high level of client satisfaction, as shown by our client net promoter score (“NPS”) of 87 as of October 31, 2024. We also invested early in building our partner network. As of March 31, 2025, we had over 50 partners. Our partners include the five largest national health plans by self-insured lives, and the top three PBMs by market share. As of that date, we had retained 100% of our partners that we chose to work with since inception, excluding partners who were acquired. We have experienced significant growth since our inception, with a recurring revenue business model. As of December 31, 2024, we had over 532,000 members and more than 2,250 clients, compared to approximately 371,000 members and approximately 1,650 clients as of December 31, 2023. Our principal executive offices are located in San Francisco, California.

Labcorp stock logo

Labcorp NYSE:LH

$326.83 -4.67 (-1.41%)
As of 03:58 PM Eastern

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.